Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04427384 · ClinicalTrials.gov registry record
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
A clinical trial of Brain Tumor and Brain Tumor, Recurrent, sponsored by GT Medical Technologies.
- Recruiting
- Registry status
- 600
- Enrollment target
- 20
- Study locations
NCT04427384 is a study of Brain Tumor and Brain Tumor, Recurrent that is actively recruiting participants, run by GT Medical Technologies. The registered enrollment target is 600 participants, above the 273-participant average among 69 other Brain Tumor trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT04427384, a study of Brain Tumor and Brain Tumor, Recurrent, is actively recruiting participants, sponsored by GT Medical Technologies.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Conditions Studied
Interventions
- DEVICE GammaTile
Study Locations (20)
Florida
- BayCare Health - Clearwater
- Ascension St. Vincent's - Jacksonville
- Miami Cancer Institute, Baptist Health South Florida - Miami
- Advent Health Orlando - Orlando
- Orlando Health - Orlando
- Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital - Tampa
- Cleveland Clinic Florida- Weston - Weston
California
- Eden Medical Center - Castro Valley
- UCSD Moores Cancer Center - La Jolla
- MemorialCare Health System - Laguna Hills
- Desert Regional Medical Center - Palm Springs
- California Pacific Medical Center, Sutter health - San Francisco
Colorado
- Centura - Denver
- Colorado Brain & Spine Institute: Swedish Campus - Englewood
Georgia
- Piedmont Healthcare - Atlanta
- Winship Cancer Institute of Emory University - Atlanta
Arizona
- HonorHeath Scottsdale Osborn Medical Center - Phoenix
Arkansas
- University of Arkansas Medical Center - Little Rock
Idaho
- St. Alphonsus Regional Medical Center - Boise
Indiana
- Goodman Campbell Brain and Spine - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2028-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04427384
The ClinicalTrials.gov registry entry for NCT04427384 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 273-participant average among 69 other Brain Tumor trials with a reported enrollment target (120% higher). The listed sponsor is GT Medical Technologies, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which GammaTile is the first listed.
NCT04427384 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04427384 about?
NCT04427384 is a clinical study titled "Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)". The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
What is the current status of trial NCT04427384?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2020-09-11. Estimated completion is 2028-12-31.
What conditions does trial NCT04427384 study?
This clinical trial studies the following conditions: Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma.
What interventions are being tested in trial NCT04427384?
The interventions under investigation include: GammaTile (DEVICE).
Who is sponsoring clinical trial NCT04427384?
This trial is sponsored by GT Medical Technologies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04427384 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.